Tirzepatide
Overview
Dual GIP/GLP-1 receptor agonist showing superior weight loss results compared to semaglutide. FDA-approved for type 2 diabetes and obesity.
Reported benefits
Enhanced weight loss, improved insulin sensitivity, better glycemic control, cardiovascular benefits
Protocols & dosing
Typical dosage: 2.5-15 mg (weekly).
Detailed dosing protocols have not yet been catalogued.
FDA & legal status
Tirzepatide is approved by the U.S. Food and Drug Administration for one or more clinical indications. Refer to the prescribing information for full safety and dosing details.
| Country | Status |
|---|---|
| United States | FDA approved |
| United Kingdom | Prescription-only / not licensed |
| Canada | Prescription-only / Schedule F if licensed |
| Australia | TGA-scheduled |
Vendor information
PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.
Side effects & safety
Reported side effects: Similar to semaglutide: GI disturbances, nausea, potential pancreatitis
References
No external sources have been catalogued for this article yet.
Related peptides
- AOD-9604 — Fat loss, metabolic enhancement
- CagriSema — Combination therapy
- Dulaglutide — Weekly GLP-1 (Trulicity)
- Fragment 176-191 — HGH fragment for fat loss
- Leptin — Satiety hormone
- Liraglutide — FDA-approved GLP-1 for weight loss